Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FPA Medical Management - FPAMQ -- Ignore unavailable to you. Want to Upgrade?

To: ezstock who wrote (465)	4/28/1998 3:48:00 PM
From: Douglas V. Fant	Respond to of 1110

ezstock, I believe (without absolutely any verifying information) that FPAM may have gotten overextended by its acquisitions. That's the bad news. On the other hand in terms of percentage price drop from $24/share last March, this stock has been pushed down almost 60% in price. That is about the same amount of price drop that Oxford and Med partners suffered when they had some problems. So IMO the "good news" is that the "bad news" (if there is any! But let's assume that there is some) has been fully reflected in the stock's price. Thus we are now at the point pricewise that it does not matter IMO what the "bad news" is that FPAM may have to report. At this point it is irrelevant. The key now will be what plan Dr. Dresnick and FPAM produce to move FPAM forward. If the plan looks convincing to the investing public, then FPAM will move forward... I'm betting that Dr. Dresnick will produce such a plan.... Let's not forget that this is a $1b Company.... Sincerely, Doug F.